GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (NYSE:GKOS) » Definitions » Cyclically Adjusted PS Ratio

Glaukos (Glaukos) Cyclically Adjusted PS Ratio : 16.33 (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Glaukos Cyclically Adjusted PS Ratio?

As of today (2024-04-28), Glaukos's current share price is $99.48. Glaukos's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $6.09. Glaukos's Cyclically Adjusted PS Ratio for today is 16.33.

The historical rank and industry rank for Glaukos's Cyclically Adjusted PS Ratio or its related term are showing as below:

GKOS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 9.92   Med: 14.2   Max: 16.33
Current: 16.33

During the past years, Glaukos's highest Cyclically Adjusted PS Ratio was 16.33. The lowest was 9.92. And the median was 14.20.

GKOS's Cyclically Adjusted PS Ratio is ranked worse than
94.41% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 2.11 vs GKOS: 16.33

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Glaukos's adjusted revenue per share data for the three months ended in Dec. 2023 was $1.685. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $6.09 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Glaukos Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Glaukos's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Cyclically Adjusted PS Ratio Chart

Glaukos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 13.05

Glaukos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 12.34 13.05

Competitive Comparison of Glaukos's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Glaukos's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Glaukos's Cyclically Adjusted PS Ratio falls into.



Glaukos Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Glaukos's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=99.48/6.09
=16.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Glaukos's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.685/129.4194*129.4194
=1.685

Current CPI (Dec. 2023) = 129.4194.

Glaukos Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.331 99.695 0.430
201406 0.446 100.560 0.574
201409 0.487 100.428 0.628
201412 0.567 99.070 0.741
201503 0.494 99.621 0.642
201506 6.097 100.684 7.837
201509 0.594 100.392 0.766
201512 0.630 99.792 0.817
201603 0.646 100.470 0.832
201606 0.789 101.688 1.004
201609 0.799 101.861 1.015
201612 0.895 101.863 1.137
201703 0.951 102.862 1.197
201706 1.203 103.349 1.506
201709 1.073 104.136 1.334
201712 1.204 104.011 1.498
201803 1.157 105.290 1.422
201806 1.235 106.317 1.503
201809 1.235 106.507 1.501
201812 1.500 105.998 1.831
201903 1.492 107.251 1.800
201906 1.607 108.070 1.924
201909 1.589 108.329 1.898
201912 1.196 108.420 1.428
202003 1.264 108.902 1.502
202006 0.712 108.767 0.847
202009 1.450 109.815 1.709
202012 1.624 109.897 1.912
202103 1.487 111.754 1.722
202106 1.686 114.631 1.904
202109 1.515 115.734 1.694
202112 1.561 117.630 1.717
202203 1.367 121.301 1.458
202206 1.535 125.017 1.589
202209 1.497 125.227 1.547
202212 1.492 125.222 1.542
202303 1.543 127.348 1.568
202306 1.665 128.729 1.674
202309 1.603 129.860 1.598
202312 1.685 129.419 1.685

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Glaukos  (NYSE:GKOS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Glaukos Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Glaukos's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos (Glaukos) Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Executives
Alex R. Thurman officer: SVP & Chief Financial Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Joseph E Gilliam officer: CFO, SVP Corporate Development C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677
Thomas William Burns director, 10 percent owner, officer: Chief Executive Officer C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Marc Stapley director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Gilbert H Kliman director C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Tomas Navratil officer: Chief Development Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Chris M. Calcaterra officer: Chief Commercial Officer C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Jonathan Silverstein director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard L Harrison officer: Treasurer, CFO & Secretary 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022